Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Recruiting now · Phase 2
Conditions studied: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
In brief
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Key facts
- Study ID
- NCT06838208
- Run by
- Anhui Provincial Cancer Hospital
- People needed
- 56
- Starts
- 2025-02-25
- Expected to finish
- 2028-04-01
- Last updated by the study team
- 2025-09-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age≥18 years old, male or female, signed Informed Consent Form (ICF);
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Histologically or cytologically confirmed ES-SCLC;
- No prior systemic treatment for ES-SCLC;
- At least one measurable (RECIST 1.1) chest lesion capable of 15Gy/5f irradiation;
- Adequate hematologic and end organ function;
You may not qualify if…
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis;
- Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;
- Was administered a live vaccine ≤ 4 weeks before treatment;
- Active autoimmune diseases or history of autoimmune diseases that may relapse;
- Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment;
- With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;
- Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to treatment, including but not limited to tuberculosis infection;
- Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to starting treatment;
Where it is running
- Anhui Cancer Hospital — Hefei, Anhui, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.